医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ZRG Partners Inc. Releases Third Quarter 2013 Life Sciences Hiring Index

2013年11月22日 AM05:55
このエントリーをはてなブックマークに追加


 

WEST ORANGE, N.J.

ZRG Partners Inc. announces the results of its third quarter Global Life Sciences Hiring Index. Q3 reflects an overall decline of 5.1%, despite the Outsourcing and Services sectors posting their highest level of hiring in the history of the Index. The Q2 sharp increase in hiring in the Asia Pacific Region has been met with an equally sharp decrease for Q3, and the declines for the quarter in Medical Devices, overall drove the hiring indexes down.

ZRG Managing Director David Fortier commented, “The index results correlate with macro-economic and policy influences. For example, the medical device sector, faced with increasingly cost-conscious customers along with a larger tax burden via the ACA, is taking a cautious approach to hiring as part of its effort to reduce costs and enhance competitiveness.” A closer look at the data highlights even larger divergences within individual sectors and geographies.

About ZRG Partners

ZRG Partners, Inc. is a global authority on talent management issues in the Life Sciences, Pharmaceutical and Medical markets. ZRG provides its clients with specialized global market expertise in executive recruitment, consulting and advisory work with a focus on data and analytics to drive great business decisions.

The Global Life Sciences Hiring Index analysis utilizes a proprietary algorithm that looks at confidential hiring within selected benchmark companies in three distinct segments. The companies in the Index generate over $634 billion in revenues and employ over 1,300,000 people globally. ZRG Partners conducts extensive direct market research in developing the data that drives the Index.

For more information about ZRG please go to www.zrgpartners.com

CONTACT

ZRG Partners
Adam
El Din
, +41-22-319-3304
European President and Global Practice
Head of Life Sciences
or
Larry
Hartmann
, +1-201-560-9900 x222
Managing Partner
or
David
Fortier
, +1-508-366-5800 x227
Managing Director

同じカテゴリーの記事 

  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続
  • ReNAgade Therapeutics继续致力于GanNA Bio和糖生物学的研究
  • ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology
  • C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing for Alzheimer’s Disease and Brain Research Market
  • BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report